{
  "id": "cluster_2_doc2",
  "content": "Hemisphere Oncology policy memo dated 12/01/2023: All cellular therapy claims now require genetic biomarker documentation (CD19+ status) and pre-authorization from Dr. Varga's team. This change stems from the CARES-2 clinical trial data showing 40% improved outcomes with proper patient selection. Implementation effective immediately for all Medicaid Advantage policies.",
  "metadata": {
    "format": "policy_document"
  }
}